FWM
UNCY icon

Frontier Wealth Management’s Unicycive Therapeutics UNCY Stock Holding History

Frontier Wealth Management’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$16K Hold
1,880
– – ﹤0.01% 390
2022
Q1 		$20K Hold
1,880
– – ﹤0.01% 401
2021
Q4 		$39K Sell
1,880
-4
-0.2% -$100 ﹤0.01% 420
2021
Q3 		$53K Buy
+1,884
New +$54K ﹤0.01% 415

Other funds holding UNCY

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
AC
Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
TCM
Tandem Capital Management Woodcliff Lake, New Jersey $200M AUM 25.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Frontier Wealth Management's UNCY Position: Q2 2022 in Review

Frontier Wealth Management held its Unicycive Therapeutics (UNCY) position steady in Q2 2022 at 1,880 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #390.

Frontier Wealth Management first reported a position in UNCY in Q3 2021 and has held it in 4 quarters since. The position peaked at $53K in Q3 2021. 15 funds tracked by Wall St. Rank hold UNCY as of Q2 2022.

  • Frontier Wealth Management held 1,880 shares of Unicycive Therapeutics worth $16K as of Q2 2022.
  • Frontier Wealth Management left its Unicycive Therapeutics share count unchanged in Q2 2022.
  • Unicycive Therapeutics made up ﹤0.01% of Frontier Wealth Management's portfolio in Q2 2022, its #390 holding.
  • Frontier Wealth Management first reported a position in Unicycive Therapeutics in Q3 2021 and has held it in 4 quarters since.
  • Frontier Wealth Management's Unicycive Therapeutics position peaked at $53K in Q3 2021.
  • 15 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2022.

Based on Frontier Wealth Management's 13F filing for Q2 2022, filed 12 Aug 2022.